GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
Related Posts
Fed Chair Faces Scrutiny — and Bats — at Major Policy Speech in Mountain Forum
A colony of bats recently took up residence at the storied Jackson Lake Lodge, where central bankers and economic policymakers will convene next week for […]
Consumers Are Pulling Back, Spooked by Tariff-Related Price Increases
Executives at several companies that sell popular products have recently pointed to signs of wariness among shoppers.
What Will Be the Next Big Media Deal?
As Skydance completes its acquisition of Paramount, the stage is set for more deal making in the crowded streaming wars.